Covid-19 Vaccine

Jim Shannon Excerpts

Tuesday 10th November 2020 Westminster Hall

[Jim Shannon (Strangford) (DUP)]

I congratulate the hon. Member for North Herefordshire (Bill Wiggin) on setting the scene so well. I am very supportive of his comments and recognise the need to get a covid vaccine in place.

The Health Secretary announced on TV this morning that, as was rumoured last night, a vaccine has been found, but at the same time he was cautious in his assessment, stating that we should welcome what is happening but remain ever mindful of the need for medical trials, which the hon. Gentleman also referred to. We watched that unfold and then later in the day we had an opportunity in the main Chamber to ask the Health Secretary questions—I think 60 right hon. and hon. Members did just that.

I welcome the fact that there might be 10 million doses of the vaccine available by the end of this year. I am particularly happy because it is a bit of good news at long last. I am always a “glass half full” person, but in the last six months it has been very difficult to try to be positive about where we are going, because the uncertainty was unreal. So today we have some good news. I know that we are not there yet, but we are moving in the right direction.

I am very pleased that Pfizer has achieved this breakthrough. However, I have some concerns at this stage that the vaccine will only be for adults—I will comment on children in a few minutes. The fact that AstraZeneca is also involved, as are many other companies around the world, shows the need to work together. I think that the Health Secretary said, in reply to one of the questions put to him today, that we need to work on an international basis, and he is right. The hon. Member for North Herefordshire also referred to that. It is really important that we realise that we are all in this together, the world over, so it is important that we get ourselves organised.

I am a diabetic—a type 2 diabetic. It is one of those chronic diseases that means I have to get the flu vaccine every year. I was fortunate enough to get the flu vaccine way back in September, I think, when I had occasion to be in the doctor’s surgery. I am not there very often, but I was down getting a check-up and they said, “Take your flu vaccine now.” I am glad that I did, because the fact of the matter is that they have run short of flu vaccines in my constituency, and in many other parts of the United Kingdom.

My question to the Health Secretary this afternoon was about the shortage of flu vaccines, and the importance of ensuring that the covid-19 vaccine, once trials are completed, is available to those who need it, so that we do not find ourselves in the same situation as many of my constituents—of a certain age, vulnerable, and who have come to me for assistance because they cannot get the vaccine. We also want to ensure that the flu vaccine that many are waiting for is available.

School teachers and care professionals—nurses, doctors and frontline workers—must be considered priorities for the vaccine once we know it is safe. If the vaccine is offered, I intend to take it, but some of my constituents have contacted me to say that they do not wish to do so. The Minister has previously said that there will be no compulsion, but my health is not just about me: it is about you, Mr Dowd, about the shadow Minister, about hon. Members and about every one of my constituents. My duty is to everyone else.

I am conscious of the time and I will not take much longer, but I want to make a plea for something that will be possible only with the support of the pharmaceutical companies and those who understand the science. I, like you, Mr Dowd, and other Members, regularly see children at my constituency surgeries with chronic asthma and other respiratory complaints. Their parents send them to school daily in fear. The young girl who drafts my speeches and does my research has a four-year-old with chronic asthma. She had to self-isolate at home from March until the beginning of August. Members might ask whether that is possible, but it is what the doctor told her to do with her child. I hope that the trials will come up with a covid-19 vaccine that children can access to.

I support the Education Minister and my own Education Minister back home in saying that children need to be at school, but they need to be safe at school. Only yesterday my grandchild was sent home because some of the pupils and teachers in the form above her showed covid-19 symptoms. They are all self-isolating for two weeks, but the fact is that we just do not know where we are with the virus. Ever mindful of the shortage with the flu vaccine, I hope we will ensure that the covid vaccine is available.

In this morning’s debate, which was also attended by the Minister, there was mention of the black, Asian and minority ethnic community and people with obesity, who are more liable, according to the stats, to have a covid-19 diagnosis. Again, when it comes to prioritising, I hope that we may include that issue.

I want to make a plea for ethnic groups across the world, as I did in the Chamber last Thursday in a debate about vaccines across the world opened by the hon. Member for North East Fife (Wendy Chamberlain). I have a personal interest in religious minorities and different ethnic groups, and I want them to have the opportunity to have the vaccine. The hon. Member for North Herefordshire mentioned that issue, and he was right. When it comes to handing out vaccines or covid-19 help and assistance, the people at the end of the queue every time are the Christians and small minority groups in countries across the world. The Health Secretary also mentioned that in passing today in the Chamber—I am referring to him quite often, and that is because I am taking note of the points that he made in the Chamber. I want to make sure that the vaccine is available not only for us, here, but for every person in the world. That comes back to the point about needing to deal with the matter internationally, and I hope that that is where we will be going.

[John Howell (Henley) (Con)]

It is a pleasure to serve under your chairmanship, Mr Dowd.

Yesterday the news was announced that Pfizer had a potential vaccine that was quite advanced. I do not know how it affected other hon. Members in the Chamber, but my heart skipped a beat. It was brilliant news, and it is not surprising that the attitude in the rest of the country has been exactly the same. It is also not surprising that the stock exchange has effectively gone wild in some areas. People are utterly depressed by the lockdown they are living in, and the news gave them hope that there is a real light at the end of the tunnel, towards which they could drive. Unlike the lights in most tunnels, it is not an oncoming train, but a real opportunity to get out of the situation we are in.

However, it was quite right of the Prime Minister to pull back a bit on that in his broadcast last night. A number of things need to be looked at and studied before we can really rejoice in what Pfizer has done. Most scientists, for example, anticipate that a vaccine will not be 100% effective. As my hon. Friend the Member for North Herefordshire (Bill Wiggin) said, it is only—I use the term lightly—90% effective. However, no vaccine will be 100% effective. We need to ensure that any approved vaccines are as effective as possible, so that they can have the greatest impact on the pandemic.

We have also heard that there is a robust pipeline of potential vaccines in development and that some have already advanced to phase 3. However, we cannot be certain when a vaccine will become available. That is why we cannot rely on a future vaccine to fight the pandemic. We must use all the tools we already have at our disposal, such as testing, contact tracing, physical distancing and masks. I also recommend co-trimoxazole, a drug that is being trialled in Bangladesh and India and that has also been trialled to a certain extent in the UK, which stops the inflammation of the lungs that comes with this terrible virus.

It is too early to know whether covid-19 vaccines will provide long-term protection. Additional research is needed to answer that question. However, the thing that encourages me from the data on people who recover from covid-19—I believe my hon. Friend has recovered from it—is that they develop an immune response that provides at least some protection against reinfection, although we do not know how strong that protection is and how long it lasts. However, that data gives me encouragement that a vaccine can duplicate and pick up on that—if it was not there, I would be very worried that a vaccine was not going to work.

A number of people have mentioned the need to do things on an international basis, and that is a great concern of mine. I happened to meet and have discussions with Dr David Nabarro, who is the special envoy on covid for the World Health Organisation. The Council of Europe—this is one of the great things that comes out of the Council of Europe made a discussion available to members of the social affairs committee. We had a virtual session with Dr Nabarro, who is an engaging, absolutely brilliant man who answers questions forthrightly—he will never make a good politician, but what I got out of the session was absolutely brilliant. To think that, in 2017, we put him forward to be the director general of the World Health Organisation, a proposal that was lost in the politics of the WHO. What a shame. What a difference that man would have made to the World Health Organisation.

The World Health Organisation has a number of programmes. It has a value framework for the allocation and prioritisation of covid-19 vaccinations. It has a road map for prioritising population groups for vaccines foe covid-19. The fair allocation framework aims to ensure that successful vaccines and treatments are shared equitably across all countries. The framework advises that once a covid-19 vaccine is shown to be safe and effective and is authorised for use—there is an argument, which I fully accept, that we could do more to make sure that different regulatory authorities are brought into line on this—all countries should receive doses in proportion to their population size to immunise the highest priority groups. That is just the first phase, after which the vaccine will roll out. If the World Health Organisation can continue in its role—I hope the United States backs off from deserting it and allows it to continue—it will be one of the things that helps to get the vaccine to all countries.

[Jim Shannon]

I am sorry for intervening, but I am concerned that those who are in good health but who happen to have a fairly deep pocket financially may think they can access this vaccine. It is really important that the people who access the vaccine for covid-19 are those who need it right now and who perhaps do not have the finance to buy it, as others might. Does the hon. Gentleman agree?

[John Howell]

The hon. Gentleman makes a good point. The World Health Organisation’s group of experts has already provided recommendations to countries about which populations should be prioritised. They include frontline health and care workers at high risk of infection, older adults and those at high risk throughout the population—people who are suffering from conditions such as heart disease and diabetes. As the second phase rolls forward and more doses are produced, the vaccine should go to groups at less risk of being infected or suffering badly.

I will finish there. This is an exciting opportunity, which we should not let go of. We should keep on top of this. Let us all hope that maybe in a few months’ time we can all be here celebrating the distribution of at least one—and perhaps more than one—vaccine that will help us out of this situation.